Back to search

Peptide record

TPDB09396

Antibacterial Anticancer Antifungal Antiparasitic Cell-penetrating Peptides Toxicity standard
20 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09396
Antibacterial Anticancer Antifungal Antiparasitic Cell-penetrating Peptides Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 Peptipedia AFP-GFuse Antifungipept CAFPdb DRAMP dbAMP dbAMP 3.0 CPPsite3.0
standard
No
A 20-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, AFP-GFuse, and other sources, with an available 3D structural model.
Sequence
KKRLKKIFKKPMVIGVTIPF
Physicochemical Analysis
C115H199N29O22S1
ANDCEQHSWY
K
2372.09
11.90
7
0
9
+7
3.96
0.050
107.00
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
0
0.00
1
Residue Composition
number
0
A
1
R
0
N
0
D
0
C
0
E
0
Q
1
G
0
H
3
I
1
L
6
K
1
M
2
F
2
P
0
S
1
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 0 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 3 L: 1 K: 6 M: 1 F: 2 P: 2 S: 0 T: 1 W: 0 Y: 0 V: 2
Chemical Descriptors
20
C115H199N29O22S1
2372.09
11.90
+7
3.96
0.050
Evidence Records 45 records
Evidence 1 Activity

Activity

MIC
Antibacterial
54 µM

Target

Enterococcus faecalis ATCC 29212 and a clinical isolate

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
DRAMP antibacterial activity supported by MIC records against bacterial target organisms. dbAMP classified as Antibacterial under the Anti-bacterial function class.
active against Gram+ E. faecalis ATCC 29212 and a clinical isolate (MIC 54 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 54 uM), S. pyogenes clinical isolate (M
Evidence 2 Activity

Activity

MIC
Antibacterial
54 µM

Target

Staphylococcus aureus ATCC 29213 and a clinical isolate

Source & Reference

dbAMP DRAMP

Other

active against Gram+ E. faecalis ATCC 29212 and a clinical isolate (MIC 54 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 54 uM), S. pyogenes clinical isolate (MIC 3.4 uM), Gram- P. aeruginosa ATCC 27853 and a clinical
Evidence 3 Activity

Activity

MIC
Antibacterial
3.4 µM

Target

Streptococcus pyogenes clinical isolate

Source & Reference

dbAMP DRAMP

Other

a clinical isolate (MIC 54 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 54 uM), S. pyogenes clinical isolate (MIC 3.4 uM), Gram- P. aeruginosa ATCC 27853 and a clinical isolate (MIC 27 uM), K. pneumoniae clinica
Evidence 4 Activity

Activity

MIC
Antibacterial
27 µM

Target

Pseudomonas aeruginosa ATCC 27853 and a clinical isolate

Source & Reference

dbAMP DRAMP

Other

9213 and a clinical isolate (MIC 54 uM), S. pyogenes clinical isolate (MIC 3.4 uM), Gram- P. aeruginosa ATCC 27853 and a clinical isolate (MIC 27 uM), K. pneumoniae clinical isolate (MIC 3.4 uM), E. coli ATCC 25922 and a clinical isolate (
Evidence 5 Activity

Activity

MIC
Antibacterial
3.4 µM

Target

Klebsiella pneumoniae clinical isolate

Source & Reference

dbAMP DRAMP

Other

isolate (MIC 3.4 uM), Gram- P. aeruginosa ATCC 27853 and a clinical isolate (MIC 27 uM), K. pneumoniae clinical isolate (MIC 3.4 uM), E. coli ATCC 25922 and a clinical isolate (MIC 0.11-3.4 uM), and A. baumannii clinical i
Evidence 6 Activity

Activity

MIC
Antibacterial
0.11-3.4 µM

Target

Escherichia coli ATCC 25922 and a clinical isolate

Source & Reference

dbAMP DRAMP

Other

CC 27853 and a clinical isolate (MIC 27 uM), K. pneumoniae clinical isolate (MIC 3.4 uM), E. coli ATCC 25922 and a clinical isolate (MIC 0.11-3.4 uM), and A. baumannii clinical isolate (MIC 1.7 uM). Fungi: active against yeasts C. parapsil
Evidence 7 Activity

Activity

MIC
Antibacterial
1.7 µM

Target

A. baumannii clinical isolate

Source & Reference

dbAMP DRAMP

Other

al isolate (MIC 3.4 uM), E. coli ATCC 25922 and a clinical isolate (MIC 0.11-3.4 uM), and A. baumannii clinical isolate (MIC 1.7 uM). Fungi: active against yeasts C. parapsilosis ATCC 22019 (MIC 40 uM), C. krusei ATCC 6258
Evidence 8 Activity

Activity

MIC
Antibacterial
40 µM

Target

C. parapsilosis ATCC 22019

Source & Reference

dbAMP DRAMP

Other

.11-3.4 uM), and A. baumannii clinical isolate (MIC 1.7 uM). Fungi: active against yeasts C. parapsilosis ATCC 22019 (MIC 40 uM), C. krusei ATCC 6258 (MIC 5 uM), C. tropicalis LABMIC 0109 (MIC 5-10 uM), C. albicans LAB
Evidence 9 Activity

Activity

MIC
Antibacterial
5 µM

Target

C. krusei ATCC 6258

Source & Reference

dbAMP DRAMP

Other

solate (MIC 1.7 uM). Fungi: active against yeasts C. parapsilosis ATCC 22019 (MIC 40 uM), C. krusei ATCC 6258 (MIC 5 uM), C. tropicalis LABMIC 0109 (MIC 5-10 uM), C. albicans LABMIC 0107 or 0108 (MIC 10 uM), C.
Evidence 10 Activity

Activity

MIC
Antibacterial
5-10 µM

Target

C. tropicalis LABMIC 0109

Source & Reference

dbAMP DRAMP

Other

ve against yeasts C. parapsilosis ATCC 22019 (MIC 40 uM), C. krusei ATCC 6258 (MIC 5 uM), C. tropicalis LABMIC 0109 (MIC 5-10 uM), C. albicans LABMIC 0107 or 0108 (MIC 10 uM), C. parapsilosis LABMIC 0113 (MIC 5 uM), C.
Evidence 11 Activity

Activity

MIC
Antibacterial
10 µM

Target

Candida albicans LABMIC 0107 or 0108

Source & Reference

dbAMP DRAMP

Other

019 (MIC 40 uM), C. krusei ATCC 6258 (MIC 5 uM), C. tropicalis LABMIC 0109 (MIC 5-10 uM), C. albicans LABMIC 0107 or 0108 (MIC 10 uM), C. parapsilosis LABMIC 0113 (MIC 5 uM), C. laurentii LABMIC 0404 (MIC 5 uM), Dermatophyt
Evidence 12 Activity

Activity

MIC
Antibacterial
5 µM

Target

C. parapsilosis LABMIC 0113

Source & Reference

dbAMP DRAMP

Other

M), C. tropicalis LABMIC 0109 (MIC 5-10 uM), C. albicans LABMIC 0107 or 0108 (MIC 10 uM), C. parapsilosis LABMIC 0113 (MIC 5 uM), C. laurentii LABMIC 0404 (MIC 5 uM), Dermatophythes M-canis LABMIC 0401 (MIC >40 uM), T-
Evidence 13 Activity

Activity

MIC
Antibacterial
5 µM

Target

C. laurentii LABMIC 0404

Source & Reference

dbAMP DRAMP

Other

uM), C. albicans LABMIC 0107 or 0108 (MIC 10 uM), C. parapsilosis LABMIC 0113 (MIC 5 uM), C. laurentii LABMIC 0404 (MIC 5 uM), Dermatophythes M-canis LABMIC 0401 (MIC >40 uM), T-rubrum LABMIC 0203 or 0204 (MIC > 40
Evidence 14 Activity

Activity

MIC
Antifungal
54 µM

Target

Enterococcus faecalis ATCC 29212 and a clinical isolate

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
DRAMP antifungal activity supported by activity records against fungal target organisms. dbAMP classified under the Anti-fungal function class.
active against Gram+ E. faecalis ATCC 29212 and a clinical isolate (MIC 54 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 54 uM), S. pyogenes clinical isolate (M
Evidence 15 Activity

Activity

MIC
Antifungal
54 µM

Target

Staphylococcus aureus ATCC 29213 and a clinical isolate

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

active against Gram+ E. faecalis ATCC 29212 and a clinical isolate (MIC 54 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 54 uM), S. pyogenes clinical isolate (MIC 3.4 uM), Gram- P. aeruginosa ATCC 27853 and a clinical
Evidence 16 Activity

Activity

MIC
Antifungal
3.4 µM

Target

Streptococcus pyogenes clinical isolate

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

a clinical isolate (MIC 54 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 54 uM), S. pyogenes clinical isolate (MIC 3.4 uM), Gram- P. aeruginosa ATCC 27853 and a clinical isolate (MIC 27 uM), K. pneumoniae clinica
Evidence 17 Activity

Activity

MIC
Antifungal
27 µM

Target

Pseudomonas aeruginosa ATCC 27853 and a clinical isolate

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

9213 and a clinical isolate (MIC 54 uM), S. pyogenes clinical isolate (MIC 3.4 uM), Gram- P. aeruginosa ATCC 27853 and a clinical isolate (MIC 27 uM), K. pneumoniae clinical isolate (MIC 3.4 uM), E. coli ATCC 25922 and a clinical isolate (
Evidence 18 Activity

Activity

MIC
Antifungal
3.4 µM

Target

Klebsiella pneumoniae clinical isolate

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

isolate (MIC 3.4 uM), Gram- P. aeruginosa ATCC 27853 and a clinical isolate (MIC 27 uM), K. pneumoniae clinical isolate (MIC 3.4 uM), E. coli ATCC 25922 and a clinical isolate (MIC 0.11-3.4 uM), and A. baumannii clinical i
Evidence 19 Activity

Activity

MIC
Antifungal
0.11-3.4 µM

Target

Escherichia coli ATCC 25922 and a clinical isolate

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

CC 27853 and a clinical isolate (MIC 27 uM), K. pneumoniae clinical isolate (MIC 3.4 uM), E. coli ATCC 25922 and a clinical isolate (MIC 0.11-3.4 uM), and A. baumannii clinical isolate (MIC 1.7 uM). Fungi: active against yeasts C. parapsil
Evidence 20 Activity

Activity

MIC
Antifungal
1.7 µM

Target

A. baumannii clinical isolate

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

al isolate (MIC 3.4 uM), E. coli ATCC 25922 and a clinical isolate (MIC 0.11-3.4 uM), and A. baumannii clinical isolate (MIC 1.7 uM). Fungi: active against yeasts C. parapsilosis ATCC 22019 (MIC 40 uM), C. krusei ATCC 6258
Evidence 21 Activity

Activity

MIC
Antifungal
40 µM

Target

C. parapsilosis ATCC 22019

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

.11-3.4 uM), and A. baumannii clinical isolate (MIC 1.7 uM). Fungi: active against yeasts C. parapsilosis ATCC 22019 (MIC 40 uM), C. krusei ATCC 6258 (MIC 5 uM), C. tropicalis LABMIC 0109 (MIC 5-10 uM), C. albicans LAB
Evidence 22 Activity

Activity

MIC
Antifungal
5 µM

Target

C. krusei ATCC 6258

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

solate (MIC 1.7 uM). Fungi: active against yeasts C. parapsilosis ATCC 22019 (MIC 40 uM), C. krusei ATCC 6258 (MIC 5 uM), C. tropicalis LABMIC 0109 (MIC 5-10 uM), C. albicans LABMIC 0107 or 0108 (MIC 10 uM), C.
Evidence 23 Activity

Activity

MIC
Antifungal
5-10 µM

Target

C. tropicalis LABMIC 0109

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

ve against yeasts C. parapsilosis ATCC 22019 (MIC 40 uM), C. krusei ATCC 6258 (MIC 5 uM), C. tropicalis LABMIC 0109 (MIC 5-10 uM), C. albicans LABMIC 0107 or 0108 (MIC 10 uM), C. parapsilosis LABMIC 0113 (MIC 5 uM), C.
Evidence 24 Activity

Activity

MIC
Antifungal
10 µM

Target

Candida albicans LABMIC 0107 or 0108

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

019 (MIC 40 uM), C. krusei ATCC 6258 (MIC 5 uM), C. tropicalis LABMIC 0109 (MIC 5-10 uM), C. albicans LABMIC 0107 or 0108 (MIC 10 uM), C. parapsilosis LABMIC 0113 (MIC 5 uM), C. laurentii LABMIC 0404 (MIC 5 uM), Dermatophyt
Evidence 25 Activity

Activity

MIC
Antifungal
5 µM

Target

C. parapsilosis LABMIC 0113

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

M), C. tropicalis LABMIC 0109 (MIC 5-10 uM), C. albicans LABMIC 0107 or 0108 (MIC 10 uM), C. parapsilosis LABMIC 0113 (MIC 5 uM), C. laurentii LABMIC 0404 (MIC 5 uM), Dermatophythes M-canis LABMIC 0401 (MIC >40 uM), T-
Evidence 26 Activity

Activity

MIC
Antifungal
5 µM

Target

C. laurentii LABMIC 0404

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

uM), C. albicans LABMIC 0107 or 0108 (MIC 10 uM), C. parapsilosis LABMIC 0113 (MIC 5 uM), C. laurentii LABMIC 0404 (MIC 5 uM), Dermatophythes M-canis LABMIC 0401 (MIC >40 uM), T-rubrum LABMIC 0203 or 0204 (MIC > 40
Evidence 27 Activity

Activity

MIC
Antiparasitic
54 µM

Target

Enterococcus faecalis ATCC 29212 and a clinical isolate

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets. dbAMP 3.0 classified under the Anti-parasitic function class.
active against Gram+ E. faecalis ATCC 29212 and a clinical isolate (MIC 54 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 54 uM), S. pyogenes clinical isolate (M
Evidence 28 Activity

Activity

MIC
Antiparasitic
54 µM

Target

Staphylococcus aureus ATCC 29213 and a clinical isolate

Source & Reference

dbAMP 3.0 DRAMP

Other

active against Gram+ E. faecalis ATCC 29212 and a clinical isolate (MIC 54 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 54 uM), S. pyogenes clinical isolate (MIC 3.4 uM), Gram- P. aeruginosa ATCC 27853 and a clinical
Evidence 29 Activity

Activity

MIC
Antiparasitic
3.4 µM

Target

Streptococcus pyogenes clinical isolate

Source & Reference

dbAMP 3.0 DRAMP

Other

a clinical isolate (MIC 54 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 54 uM), S. pyogenes clinical isolate (MIC 3.4 uM), Gram- P. aeruginosa ATCC 27853 and a clinical isolate (MIC 27 uM), K. pneumoniae clinica
Evidence 30 Activity

Activity

MIC
Antiparasitic
27 µM

Target

Pseudomonas aeruginosa ATCC 27853 and a clinical isolate

Source & Reference

dbAMP 3.0 DRAMP

Other

9213 and a clinical isolate (MIC 54 uM), S. pyogenes clinical isolate (MIC 3.4 uM), Gram- P. aeruginosa ATCC 27853 and a clinical isolate (MIC 27 uM), K. pneumoniae clinical isolate (MIC 3.4 uM), E. coli ATCC 25922 and a clinical isolate (
Evidence 31 Activity

Activity

MIC
Antiparasitic
3.4 µM

Target

Klebsiella pneumoniae clinical isolate

Source & Reference

dbAMP 3.0 DRAMP

Other

isolate (MIC 3.4 uM), Gram- P. aeruginosa ATCC 27853 and a clinical isolate (MIC 27 uM), K. pneumoniae clinical isolate (MIC 3.4 uM), E. coli ATCC 25922 and a clinical isolate (MIC 0.11-3.4 uM), and A. baumannii clinical i
Evidence 32 Activity

Activity

MIC
Antiparasitic
0.11-3.4 µM

Target

Escherichia coli ATCC 25922 and a clinical isolate

Source & Reference

dbAMP 3.0 DRAMP

Other

CC 27853 and a clinical isolate (MIC 27 uM), K. pneumoniae clinical isolate (MIC 3.4 uM), E. coli ATCC 25922 and a clinical isolate (MIC 0.11-3.4 uM), and A. baumannii clinical isolate (MIC 1.7 uM). Fungi: active against yeasts C. parapsil
Evidence 33 Activity

Activity

MIC
Antiparasitic
1.7 µM

Target

A. baumannii clinical isolate

Source & Reference

dbAMP 3.0 DRAMP

Other

al isolate (MIC 3.4 uM), E. coli ATCC 25922 and a clinical isolate (MIC 0.11-3.4 uM), and A. baumannii clinical isolate (MIC 1.7 uM). Fungi: active against yeasts C. parapsilosis ATCC 22019 (MIC 40 uM), C. krusei ATCC 6258
Evidence 34 Activity

Activity

MIC
Antiparasitic
40 µM

Target

C. parapsilosis ATCC 22019

Source & Reference

dbAMP 3.0 DRAMP

Other

.11-3.4 uM), and A. baumannii clinical isolate (MIC 1.7 uM). Fungi: active against yeasts C. parapsilosis ATCC 22019 (MIC 40 uM), C. krusei ATCC 6258 (MIC 5 uM), C. tropicalis LABMIC 0109 (MIC 5-10 uM), C. albicans LAB
Evidence 35 Activity

Activity

MIC
Antiparasitic
5 µM

Target

C. krusei ATCC 6258

Source & Reference

dbAMP 3.0 DRAMP

Other

solate (MIC 1.7 uM). Fungi: active against yeasts C. parapsilosis ATCC 22019 (MIC 40 uM), C. krusei ATCC 6258 (MIC 5 uM), C. tropicalis LABMIC 0109 (MIC 5-10 uM), C. albicans LABMIC 0107 or 0108 (MIC 10 uM), C.
Evidence 36 Activity

Activity

MIC
Antiparasitic
5-10 µM

Target

C. tropicalis LABMIC 0109

Source & Reference

dbAMP 3.0 DRAMP

Other

ve against yeasts C. parapsilosis ATCC 22019 (MIC 40 uM), C. krusei ATCC 6258 (MIC 5 uM), C. tropicalis LABMIC 0109 (MIC 5-10 uM), C. albicans LABMIC 0107 or 0108 (MIC 10 uM), C. parapsilosis LABMIC 0113 (MIC 5 uM), C.
Evidence 37 Activity

Activity

MIC
Antiparasitic
10 µM

Target

Candida albicans LABMIC 0107 or 0108

Source & Reference

dbAMP 3.0 DRAMP

Other

019 (MIC 40 uM), C. krusei ATCC 6258 (MIC 5 uM), C. tropicalis LABMIC 0109 (MIC 5-10 uM), C. albicans LABMIC 0107 or 0108 (MIC 10 uM), C. parapsilosis LABMIC 0113 (MIC 5 uM), C. laurentii LABMIC 0404 (MIC 5 uM), Dermatophyt
Evidence 38 Activity

Activity

MIC
Antiparasitic
5 µM

Target

C. parapsilosis LABMIC 0113

Source & Reference

dbAMP 3.0 DRAMP

Other

M), C. tropicalis LABMIC 0109 (MIC 5-10 uM), C. albicans LABMIC 0107 or 0108 (MIC 10 uM), C. parapsilosis LABMIC 0113 (MIC 5 uM), C. laurentii LABMIC 0404 (MIC 5 uM), Dermatophythes M-canis LABMIC 0401 (MIC >40 uM), T-
Evidence 39 Activity

Activity

MIC
Antiparasitic
5 µM

Target

C. laurentii LABMIC 0404

Source & Reference

dbAMP 3.0 DRAMP

Other

uM), C. albicans LABMIC 0107 or 0108 (MIC 10 uM), C. parapsilosis LABMIC 0113 (MIC 5 uM), C. laurentii LABMIC 0404 (MIC 5 uM), Dermatophythes M-canis LABMIC 0401 (MIC >40 uM), T-rubrum LABMIC 0203 or 0204 (MIC > 40
Evidence 40 Activity

Activity

50% Hemolysis
Toxicity
>200 µM
Hemolytic Cytotoxic
50% Hemolysis | >200 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Evidence 41 Activity

Activity

20% Killing
Toxicity
100 µM
Cytotoxic
20% Killing | 100 | µM | target cell: Human fibroblasts

Target

Human fibroblasts

Source & Reference

NA
DBAASP
Structural Dissection of Crotalicidin, a Rattlesnake Venom Cathelicidin, Retrieves a Fragment with Antimicrobial and Antitumor Activity. | J Med Chem | 2015
Evidence 42 Activity

Activity

EC50
Toxicity
>100 µM
Cytotoxic
EC50 | >100 | µM | target cell: Monkey kidney epithelial cells LLC-MK2

Target

Monkey kidney epithelial cells LLC-MK2

Source & Reference

NA
DBAASP
Antichagasic effect of crotalicidin, a cathelicidin-like vipericidin, found in Crotalus durissus terrificus rattlesnake's venom gland. | Parasitology | 2017
Evidence 43 Activity

Activity

0% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
0% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structural Dissection of Crotalicidin, a Rattlesnake Venom Cathelicidin, Retrieves a Fragment with Antimicrobial and Antitumor Activity. | J Med Chem | 2015
Evidence 44 Activity

Activity

7% Hemolysis
Toxicity
400 µM
Hemolytic Cytotoxic
7% Hemolysis | 400 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structural Dissection of Crotalicidin, a Rattlesnake Venom Cathelicidin, Retrieves a Fragment with Antimicrobial and Antitumor Activity. | J Med Chem | 2015
Evidence 45 Activity

Activity

Toxicity
Cytotoxic
- | NA | target cell: Human fibroblasts

Target

Human fibroblasts

Source & Reference

NA
DBAASP
Structural Dissection of Crotalicidin, a Rattlesnake Venom Cathelicidin, Retrieves a Fragment with Antimicrobial and Antitumor Activity. | J Med Chem | 2015